News articles about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Moleculin Biotech earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.7303750675033 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Summary of Price Movements: Moleculin Biotech, Inc. (MBRX) stock price completes at $1.86 with closing change of … (nasdaqexpress.com)
- Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017 (finance.yahoo.com)
- Moleculin Bio adds Cleveland medical centers to U.S. Annamycin study (seekingalpha.com)
- Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials (finance.yahoo.com)
Shares of NASDAQ MBRX opened at $1.80 on Monday. The firm has a market capitalization of $46.38, a price-to-earnings ratio of -3.83 and a beta of -1.44. Moleculin Biotech has a 52-week low of $0.71 and a 52-week high of $3.75.
ILLEGAL ACTIVITY WARNING: “Moleculin Biotech (NASDAQ:MBRX) Earning Somewhat Positive Media Coverage, Report Finds” was published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/04/02/moleculin-biotech-mbrx-getting-somewhat-favorable-news-coverage-accern-reports/2002441.html.
About Moleculin Biotech
Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.